KMTS · XBRL financial data

Kestra Medical Technologies financial statements, every quarter

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (KMTS's year ends in late April)

In thousands of dollars	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY25Jul 31, 2025	Q2 FY25Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY26Jul 31, 2026
Revenue from contracts with customers	15,090	17,233*	19,371	22,565	24,552	28,638*	30,971
Cost of goods and services sold	8,543	9,600*	10,520	11,141	11,646	12,956*	13,473
Gross profit	6,547	7,633*	8,851	11,424	12,906	15,682*	17,498
Research and development	3,353	5,386*	4,001	4,878	4,972	5,634*	6,796
Selling, general and administrative	23,795	50,459*	33,728	38,301	42,699	49,392*	48,359
Total operating expenses	27,148	55,845*	37,729	43,179	47,671	55,026*	55,155
Operating income (loss)	(20,601)	(48,212)*	(28,878)	(31,755)	(34,765)	(39,344)*	(37,657)
Interest income	628	1,656*	2,167	1,796	2,163	2,226*	2,125
Interest expense	1,783	1,760*	1,912	1,901	1,888	1,844*	1,929
Other income (expense)	15	(2,693)*	2,830	(891)	359	319*	(272)
Income tax expense (benefit)	18	102*	33	34	35	192*	50
Net income (loss)	(21,509)	(52,053)*	(25,826)	(32,785)	(34,166)	(38,835)*	(44,087)
Earnings per share, basic USD per share	(1.25)	—	(0.50)	(0.64)	(0.61)	(0.67)*	(0.75)
Earnings per share, diluted USD per share	(1.25)	—	(0.50)	(0.64)	(0.61)	(0.67)*	(0.75)
Weighted average shares, basic thousands of shares	19,885	—	51,305	51,376	55,848	58,345*	58,566
Weighted average shares, diluted thousands of shares	19,885	—	51,305	51,376	55,848	58,345*	58,566

Fiscal quarters (KMTS's year ends in late April)

In thousands of dollars	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY25Jul 31, 2025	Q2 FY25Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY26Jul 31, 2026
Cash and cash equivalents	54,352	237,595	201,214	175,424	291,321	99,710	68,558
Short-term investments	—	—	—	—	—	96,724	130,353
Prepaid and other current assets	—	3,080	3,429	2,659	3,204	4,677	4,518
Total current assets	—	255,328	220,691	195,414	314,063	222,359	226,273
Property and equipment, net	—	34,830	40,376	45,932	53,799	59,090	63,656
Right-of-use asset	—	2,078	2,046	1,960	3,419	3,364	3,263
Total assets	—	295,744	266,296	246,701	379,342	358,465	347,355
Accounts payable	—	23,961	18,570	20,209	24,023	27,295	25,961
Accrued liabilities	—	13,829	13,650	15,494	18,898	23,046	22,285
Total current liabilities	—	37,977	32,256	35,756	42,931	50,372	48,269
Long-term debt	—	41,098	41,486	41,873	42,261	42,649	72,495
Lease liability, non-current	—	3,026	3,067	2,874	4,276	4,111	3,928
Total liabilities	—	90,338	82,137	82,620	91,353	98,807	124,998
Accumulated deficit	—	(520,249)	(546,075)	(578,860)	(613,026)	(651,861)	(695,948)
Total liabilities and equity	—	295,744	266,296	246,701	379,342	358,465	347,355
Common shares outstanding (cover page) thousands of shares	51,349	51,349	51,449	58,349	58,373	58,602	59,562

Fiscal quarters (KMTS's year ends in late April)

In thousands of dollars	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY25Jul 31, 2025	Q2 FY25Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY26Jul 31, 2026
Net income (loss)	(21,509)	(52,053)*	(25,826)	(32,785)	(34,166)	(38,835)*	(44,087)
Stock-based compensation	459*	22,312*	4,579	8,653*	10,108*	10,304*	9,517
Depreciation and amortization	1,888*	1,836*	2,028	2,373*	1,983*	2,325*	2,664
Net cash from operating activities	(17,997)*	(24,056)*	(26,274)	(18,343)*	(18,366)*	(18,720)*	(32,295)
Purchases of property and equipment	4,063*	7,389*	8,166	7,265*	9,797*	9,664*	8,335
Net cash from investing activities	(4,450)*	(7,404)*	(8,232)	(7,420)*	(14,919)*	(172,706)*	(21,352)
Proceeds from issuing common stock	—	year only	—	—	—	0*	—
Proceeds from long-term debt	—	—	—	—	—	—	75,000
Repayments of long-term debt	—	—	—	—	—	—	46,395
Net cash from financing activities	(119)*	214,703*	(1,875)	(27)*	149,182*	(185)*	22,495
Net change in cash	(22,566)*	183,243*	(36,381)	(25,790)*	115,897*	(191,611)*	(31,152)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Kestra Medical Technologies	68,558	30,971	(32,295)	59.6M	4.9 quarters	Q1 FY26 10-QJul 31, 2026
Beta Bionics	81,551	35,505	(12,287)*	54.4M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Cadre Holdings	53,984	207,126	22,131*	42.8M	—	Q2 FY26 10-QJun 30, 2026
Avanos Medical	65,600	182,200	(12,300)	46.8M	5.3 quarters	Q1 FY26 10-QMar 31, 2026
Mimedx Group	120,791	62,283	3,919*	145.9M	—	Q3 FY26 10-QSep 30, 2026
Embecta	214,700	271,700	41,800*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
SI-BONE	33,128	56,010	777*	44.8M	—	Q2 FY26 10-QJun 30, 2026
Biolife Solutions	23,997	not reported	6,348*	48.9M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.